| Document |
Document Title |
|
WO/2011/047055A2 |
The invention pertains to compound of Formula (I) wherein X, Y, Z, R1, R2, R3, R4, A and A' are as described hereinabove. Formula (I) and (II) compounds can be used in pharmaceutical compositions, useful for the treatment of diseases.
|
|
WO/2011/005731A2 |
The invention encompasses a novel process for making 2-[(8R)-8-(3,5-Difluorophenyl)-10-oxo-6,9-diazaspiro[4.5]dec
-9-yl]-N-[(2R)-2'-oxo-1,1',2',3-tetrahydrospiro[indene-2,3'-
pyrrolo[2,3-b]pyridin]-5-yl]acetamide, which is a CGRP recepto...
|
|
WO/2010/105367A1 |
The present application describes general process for the preparation of amino-substitued gamma-lactams involving the reaction of synthons of the general Formulae (I) and (VI): with amines. The processes are amenable to solid phase synth...
|
|
WO/2010/072310A1 |
The present invention relates to a novel benzoxathiazine derivatives of the formula (I), wherein R1, R2, R3, R4, R5 and R6 are as defined in the description, to a plurality of methods for the production thereof, and to the use thereof as...
|
|
WO/2010/044371A1 |
A sweet taste receptor agonist such as acesulfame K, sucralose, saccharin or glycyrrhizin can be used as an active ingredient for an insulin secretion stimulator. A candidate substance for an insulin secretion stimulator can be screened...
|
|
WO/2009/029317A2 |
The present disclosure encompasses compounds and compositions that are useful as specific AI-2 antagonists for the control of bacterial quorum sensing. Although the AI-2 antagonists according to the present disclosure may not have bacter...
|
|
WO/2009/019534A2 |
The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1 -propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compounds that will yield or generate 3APS, ...
|
|
WO/2008/102908A1 |
Disclosed is a novel herbicide. Specifically disclosed is a haloalkylsulfonanilide derivative represented by the general formula (1) below, or an agrochemically acceptable salt thereof. (In the formula, Q represents -N(R5)SO2R6, wherein ...
|
|
WO/2008/073956A2 |
The present invention is directed to cyclic sulfonamide derivatives of formula (I): or a pharmaceutically acceptable salt thereof, which are monoamine reuptake inhibitors, compositions containing these derivatives, and methods of their u...
|
|
WO/2008/016099A1 |
Disclosed is a method for simply and efficiently producing a high-quality potassium salt of a 3,4-dihydro-1,2,3-oxathiazin-4-one-2,2-dioxide compound. Specifically disclosed is a production method comprising a step wherein a 3,4-dihydro-...
|
|
WO/2008/016100A1 |
Disclosed is a method for simply and efficiently producing a high-quality 3,4-dihydro-1,2,3-oxathiazin-4-one-2,2-dioxide compound or a salt thereof. Specifically, when a compound represented by the formula (2) below or a salt thereof is ...
|
|
WO/2007/123853A2 |
Disclosed are compounds of Formula (1), including all geometric and stereoisomers, N-oxides, and salts thereof wherein G is O or NR3; U is C(=O), S(=O), C(=S), or S(O)2; Z is N or CR2; R1 is cyano; or C1-C6 alkyl, C2-C6 alkenyl, C2-C6 al...
|
|
WO/2007/024717A2 |
The present invention provides compounds of Formula I, (I) and salts, hydrates, solvates, complexes, and prodrugs thereof. The present invention further provides methods for synthesizing compounds of Formula I. The invention additionally...
|
|
WO/2007/001015A1 |
[PROBLEMS] To provide: a process for producing an optically active aminopentane derivative which is expected to be useful as a psychotropic agent, an antidepressant, an anti-Perkinson agent, an anti-Alzhemer disease, an anti-apoptotic ag...
|
|
WO/2006/102645A1 |
The invention is directed to novel vanilloid receptor type 1 (VR1) ligands. More specifically, the invention relates to novel biaryl-derived amides that are potent antagonists or agonists of VR1. Pharmaceutical and veterinary composition...
|
|
WO/2006/074940A2 |
The invention relates to novel macrocyclic compounds of the formula in which R1, R3, V1, V2, X1, X2, Y, Z, Ar, AA and n are as defined in the specification, the number of ring atoms included in the macrocyclic ring being 14, 15, 16, 17 o...
|
|
WO/2006/016610A2 |
A method of stabilizing amine oxides that even under acidic and basic conditions, inhibits any formation of hydrophobic salts from the amine oxides to thereby enable stably handling of the amine oxides. There is provided a method of stab...
|
|
WO/2005/072376A2 |
One aspect of the present invention relates to ionic liquids comprising an anionic sweetener. Another aspect of the present invention relates to the use of an ionic liquid of the present invention comprising a pendant Bronsted-acidic gro...
|
|
WO/2005/049592A1 |
The invention provides a process for preparing intermediate of ezetimibe, which shows hypocholesterolemic activity. Thus 3-[5-(4-fluorophenyl)-1,5-dioxopentyl]-4-phenyl-2-oxazolidin
one is reduced with (-)-DIP chloride to obtain 3-[(5S)-...
|
|
WO/2005/034856A2 |
The invention provides a prodrug platform technology for improving the therapeutic value of a variety of parent drug compounds by altering and improving drug characteristics such as aqueous solubility, hydrolytic stability, therapeutic i...
|
|
WO/2005/003106A1 |
The present invention relates to macrocyclic compounds of formula (I), wherein R1, is (C1-8)alkyl, (C1-4)alkoxy(C1-4)alkyl, hydroxy(C1-6)alkyl, (C1-4)alkylthio(C1-4)alkyl, (C1-6)alkenyl, (C3-7)cycloalkyl, (C3-7)cycloalkyl(C1-4)alkyl, p...
|
|
WO/2005/002365A1 |
The invention relates to a method for producing a sweetener salt of formula APMH+Ace-, according to which aspartame or an aspartame derivative is reacted with acesulfamic acid in a solvent selected among one or several of the following: ...
|
|
WO/2004/080377A2 |
This invention relates to compounds of the general formula (I) useful as modulators of the KCNQ channel, to pharmaceutical compositions comprising these compounds, and to methods of treatment herewith.
|
|
WO/2004/069844A1 |
The invention relates to compounds of formula (I) wherein (A) and (B) each represent an optionally-substituted benzyl or pyridyl group, W is (b1) or (b2), Y is (CH2)n or an alkenyl or alkynyl group, n is zero or a whole number such that ...
|
|
WO/2004/041792A1 |
The invention provides compound of the Formula (I) and pharmaceutically acceptable salts or prodrugs thereof, wherein Y, Z, R1, R2, R3, R4, R5, R6, R7, R8, R9, m, n, p and q are as defined herein. The invention also provides methods for ...
|
|
WO/2004/039788A1 |
Methods for the preparation of N-arylated oxazolidinone compounds via a copper catalyzed cross coupling reaction are disclosed.
|
|
WO/2004/039785A1 |
The invention provides a new process for the preparation of compounds of formula (XI) which are useful as kappa agonists. The process involves, as a key step, a copper-mediated aryl amination.
|
|
WO/2004/026292A1 |
Antitussives containing as the active ingredient compounds represented by the general formula (I) or salts thereof: (I) (wherein A is alkoxycarbonylalkyl or the like and R is optionally protected hydroxyl, or A and R may be united to for...
|
|
WO/2004/002462A2 |
This invention relates to a method of treating ADHD by administering an alpha2delta ligand such as, for example, gabapentin or pregabalin, or a pharmaceutically acceptable salt thereof.
|
|
WO/2003/091207A2 |
This invention provides a method of preparing amine stereoisomers, which comprises stereoselectively reducing a sulfinylimine that bears on the sulfmyl group a residue of an alcohol, thiol or amine, or reacting a sulfmylimine stereoisome...
|
|
WO/2003/082928A1 |
Control agents that have an oxygen -nitrogen bond covalently bonded to a thiocarbonyl moiety are provided for living-type free radical polymerization of a wide variety of monomers, particularly vinyl monomers.
|
|
WO/2003/067332A2 |
Chemically amplified photoresist compositions comprising, (a) a compound which cures upon the action of an acid or a compound whose solubility is increased upon the action of an acid&semi and (b) a compound of the formula (Ia), (Ib), (II...
|
|
WO/2003/066549A2 |
A regio- and stereoselective two-stage synthesis of β-aminoalcohols employs a key transformation, viz., the creation of a cyclic sulfamidate from a precursor diol, mediated by Burgess-type reagents. The generality and scope of this appr...
|
|
WO/2003/032999A1 |
A compound of Formula (I) or a pharmaceutical acceptable salt thereof, or a tautomer thereof, wherein G¿1?, G¿2?, and B are as defined in the application, are selective inhibitors of MMP-13. The compounds are useful for treating diseas...
|
|
WO/2003/018029A1 |
Compounds of the structure I are useful for treating bacterial growth. The compounds may be used to treat bacterial infections in human beings and to regulate biofilm formation. Pharmaceutical compositions comprising one or more such com...
|
|
WO/2003/016295A1 |
The invention refers to a novel process for preparing the acesulfam salts, in which the sodium phenoxide or substituted sodium phenoxide and the sulfonyl chloride are used as starting materials. The process can get the acesulfam salts, e...
|
|
WO/2003/016245A1 |
The present invention is directed to the separation of enantiomers of racemates of formula (I). The separation proceeds by applying deemed racemates to continuos enantioselective chromatography like SMB. The methods predominantly is perf...
|
|
WO/2002/100399A1 |
The present invention is macrocycles of the formula (X): for treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme for the treatment of Alzheimer's disease and other dise...
|
|
WO/2002/083608A2 |
This invention encompasses novel methods of preparing sulfinamides and sulfoxides, particularly stereomerically pure sulfinamides and sulfoxides. The invention further encompasses novel compounds from which sulfinamides and sulfoxides ca...
|
|
WO/2002/067916A2 |
The invention relates to pharmaceutical salts comprised of a pharmaceutical active substance, particularly N,N-dimethylaminopropylphenol compounds or tradamol, and of at least one sugar substitute such as saccharin, cyclamate or acesulfa...
|
|
WO/2002/067651A2 |
The invention relates to pharmaceutical salts comprised of a pharmaceutical active substance and of at least one sugar substitute, to medicaments containing these salts, and to the use of these salts for producing medicaments
|
|
WO/2002/036118A2 |
This invention relates to novel heterocyclic derivatives of the formula (VII), (VIII) or (IX) in which P, Q , R1 - R6, m and n are as defined in the specification, and to pharmaceutically acceptable salts thereof. The compounds and pharm...
|
|
WO/2002/011722A1 |
The invention relates to substituted and non-substituted 3H-benzo[1,2,3]oxathiazole 2,2-dioxide, 1,3-dihydro-benzo[1,2,5]thiadiazole 2,2-dioxide and 1,3-dihydro-benzo[c]isothiazole 2,2-dioxide, in addition to the production and use there...
|
|
WO/2001/087894A1 |
Antitumour compounds have the five membered fused ring ecteinascidin structure of the formula (XIV). The present compounds lack a 1,4-bridging group as found in the ecteinascidins. They have at the C-1 position a substituent selected fro...
|
|
WO/2001/087895A1 |
Processes are provided for preparing compounds with a fused ring structure of formula (XIV). Such products include ecteinascidins and have a spiroamine-1,4-bridge. The process involving forming a 1,4 bridge using a l-labile, 10-hydroxy, ...
|
|
WO/2001/077115A1 |
Compounds having a fused ecteinascidin five ring system with a 1,4 bridge having the structure of formula (VIa or VIb) and compounds in which the -NH¿2? or -OH of the 1,4 bridge is derivatised are disclosed. Such compounds are useful in...
|
|
WO/2001/015683A1 |
The invention relates to tramadol forms of administration whose action is delayed by means of a coating and which contain the active agent tramadol in the form of tramadol saccharinate and optionally, other adjuvants.
|
|
WO/2001/015682A1 |
The invention relates to pharmaceutical salts consisting of the active agent tramadol and at least one sugar substitute. The invention also relates to medicaments containing these salts, to the use of these salts for producing medicament...
|
|
WO/2001/015667A1 |
The invention relates to oral dosage forms with controlled total-release of an active substance. Said active substance is present in the form of at least two different salts that are present in the dosage form in a solid state of aggrega...
|
|
WO/2000/071118A1 |
The invention concerns novel phospholipase A¿2? specific inhibiting compounds of general formula (I). Said novel compounds are capable of acting on PLA¿2? and are advantageously PLA¿2?snp-specific inhibiting compounds completely inact...
|
